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Abstract
Aims/hypothesis Obesity is characterised by increased
triacylglycerol storage in adipose tissue. There is in vitro
evidence for a blunted beta-adrenergically mediated lipo-
lytic response in abdominal subcutaneous adipose tissue
(SAT) of obese individuals and evidence for this at the
whole-body level in vivo. We hypothesised that the beta-
adrenergically mediated effect on lipolysis in abdominal
SAT is also impaired in vivo in obese humans.
Methods We investigated whole-body and abdominal SAT
glycerol metabolism in vivo during 3 h and 6 h [
2H5]glycerol
infusions. Arterio–venous concentration differences were
measured in 13 lean and ten obese men after an overnight
fast and during intravenous infusion of the non-selective
beta-adrenergic agonist isoprenaline [20 ng (kg fat free
mass)
−1 min
−1].
Results Lean and obese participants showed comparable
fasting glycerol uptake by SAT (9.7±3.4 vs 9.3±2.5% of total
release, p=0.92). Furthermore, obese participants showed an
increased whole-body beta-adrenergically mediated lipolytic
response versus lean participants. However, their fasting
lipolysis was blunted [glycerol rate of appearance: 7.3±0.6
vs 13.1±0.9 μmol (kg fat mass)
−1 min
−1, p<0.01], as was
the beta-adrenergically mediated lipolytic response per unit
SAT [Δ total glycerol release: 140±71 vs 394±112 nmol
(100 g tissue)
−1 min
−1, p<0.05] compared with lean
participants. Net triacylglycerol flux tended to increase in
obese compared with lean participants during beta-adrener-
gic stimulation [Δ net triacylglycerol flux: 75±32 vs 16±
11 nmol (100 g tissue)
−1 min
−1, p=0.06].
Conclusions/interpretation We demonstrated in vivo that
beta-adrenergically mediated lipolytic response is impaired
systematically and in abdominal SAT of obese versus lean
men. This may be important in the development or main-
tenance of increased triacylglycerol stores and obesity.
Keywords Adipose tissue.Arterio–venousdifferences.
Beta-adrenergicstimulation.Catecholamines.Glycerol.
Invivo.Lipolysis.Obesity.Triacylglycerol
Abbreviations
ATBF adipose tissue blood flow
FFM fat free mass
FM fat mass
Ra glycerol rate of appearance
SAT abdominal subcutaneous adipose tissue
TAG triacylglycerol
TTR tracer/tracee ratio
Introduction
Obesity is characterised by excess fat storage in adipose
tissue, in the form of triacylglycerol (TAG). A blunted fat
mobilisation, due to decreased adipose tissue lipolysis,
Diabetologia (2008) 51:320–327
DOI 10.1007/s00125-007-0866-y
J. W. E. Jocken (*): G. H. Goossens:A. M. J. van Hees:
M. van Baak: J. Stegen:W. H. M. Saris:E. E. Blaak
Department of Human Biology, Nutrition and Toxicology
Research Institute Maastricht (NUTRIM), Maastricht University,
Maastricht, The Netherlands
e-mail: J.Jocken@HB.Unimaas.nl
K. N. Frayn
Oxford Centre for Diabetes, Endocrinology and Metabolism,
University of Oxford,
Oxford, UK
M. T. W. Pakbiers
Department of Nuclear Medicine, University Hospital Maastricht,
Maastricht, The Netherlandsmight be an important factor contributing to the develop-
ment or maintenance of the expanded adipose tissue mass
in obesity. Fasting lipolysis per unit of lean body mass has
been reported to be increased in obesity, whereas a decrease
is reported when expressed per unit of fat mass (FM) [1].
The hormonal regulation of lipolysis is still under debate.
There is strong evidence from in vitro and in vivo studies
for the existence of lipolytic resistance to catecholamines
in obese individuals. Blunted whole-body catecholamine-
induced lipolysis has been shown in vivo in obese persons
[2, 3]. This impaired lipolysis did not improve after weight
reduction [4]. Furthermore, a decreased lipolytic response
to catecholamines is a feature of childhood-onset obesity
[5, 6] and is also present in adipocytes from first-degree
relatives of obese persons [7]. These observations suggest
that catecholamine resistance of lipolysis may be an impor-
tant early, and perhaps primary factor, in the development
of obesity. In vitro catecholamine resistance of lipolysis
was reported in subcutaneous adipocytes of men and women
with upper-body obesity, in relation with a decreased cell
surface density of β2-adrenoceptors [8]. We hypothesised
that beta-adrenergically mediated lipolytic response at the
whole-body and abdominal subcutaneous adipose tissue
(SAT) level is impaired in vivo in obese persons. If so, this
might contribute to the increased fat storage in this adipose
tissue depot.
To obtain an accurate estimation of lipolysis, state-
of-the-art [
2H5]glycerol tracer methodology in combination
with the measurement of arterio–venous concentration dif-
ferences across abdominal SAT was used. Obese and lean
malecontrolparticipantswereinvestigatedafteranovernight
fast and during catecholamine stimulation using the non-
selective beta-adrenergic agonist isoprenaline. The primary
outcome measures of the present study were glycerol rate of
appearance (Ra) and glycerol exchange across abdominal
SAT. A methodological issue that arises when determining
local adipose tissue glycerol release is the possibility that
adipose tissue may also take up small amounts of glycerol
[9]. A pilot study was performed to determine the time
period required to obtain a steady-state in glycerol enrich-
ment in both arterialised and venous blood draining from
adipose tissue, since a lack of isotopic equilibration may
explain previous discrepant findings on glycerol uptake [10].
Methods
Participants
Three lean (two women and one man; BMI<25 kg/m
2)
participants took part in a pilot experiment, during which
[
2H5]glycerol enrichment was measured for 6 h to deter-
mine the time required for obtaining an isotopic steady-
state. Thirteen lean (BMI<25 kg/m
2) and ten obese (BMI≥
30 kg/m
2) non-smoking normotensive men participated in
the actual SAT lipolysis study, during which [
2H5]glycerol
was infused for a 3 h period. Clinical characteristics of the
participants are summarised in Table 1. Body weight and
body density were determined after an overnight fast, as
previously described [11]. All participants were in good
health as assessed by their medical history, free of any
medication and spent no more than 3 h/week in organised
sportsactivities.TheMedicalEthicalCommitteeofMaastricht
University approved the study protocol and all participants
gave their written informed consent before participating in
the study.
Experimental protocol
Pilot study The time course in [
2H5]glycerol enrichment
was determined in order to identify when steady-state levels
were achieved (n=3). Glycerol enrichment was measured in
arterialised blood and blood draining the abdominal SAT
(adipose vein) during primed (3 μmol/kg) constant infusion
for 6 h of [
2H5]glycerol (0.20 μmol kg
−1 min
−1). Blood
samples were taken simultaneously from the two sites, both
at baseline before the start of the tracer infusion (t0 min),
and at ten time points during glycerol infusion (t60, t90,
t120, t150, t180, t210, t240, t330, t345, t360 min).
Whole-body and SAT lipolysis study Glycerol enrichment
and exchange across abdominal SAT were investigated dur-
ing primed (3 μmol/kg) constant infusion of [
2H5]glycerol
for 3 h (0.20 μmol kg
−1 min
−1). Following a 120 min base-
line period, isoprenaline was infused at a rate of 20 ng [kg
fat free mass (FFM)]
−1 min
−1 for 60 min. During the exper-
iment, heart rate was recorded continuously by means of a
three-lead ECG. When heart rate increased by more than
40 beats per min or in the event of ECG irregularities,
isoprenaline infusion was stopped (n=2, one lean and one
obese participant). Before the start of the tracer infusion an
arterialised blood sample was taken for background enrich-
Table 1 Clinical characteristics of the participants
Lean (n=13) Obese (n=10)
Age (years) 43±3 54±3
BMI (kg/m
2) 23.0±0.5 31.9±0.6
a
FM (kg) 15.2±0.8 32.4±1.2
a
WHR 0.91±0.01 1.01±0.01
a
Systolic blood pressure (mmHg) 126±3 137±4
Diastolic blood pressure (mmHg) 77±2 85±3
HOMA-IR 1.8±0.2 3.4±0.3
a
Values are mean±SEM
ap<0.05 obese vs lean
HOMA-IR, homeostatic model assessment of insulin resistance
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the arterialised and adipose vein at three baseline time
points (t90, t105 and t120 min) and at three time points
during the last 30 min of isoprenaline infusion (t150, t165
and t180 min). Adipose tissue blood flow (ATBF) was
monitored continuously using the
133Xe washout technique
[12]. ATBF results have been published previously in
another context [13].
Clinical methods
All participants were asked to refrain from drinking alcohol
and to perform no strenuous exercise for 24 h before the
study. Participants came to the laboratory by car or bus at
08:00 hours after an overnight fast. Three cannulas were
inserted before the start of the experiment. Arterialised
venous blood was obtained through a 20-gauge cannula
inserted retrogradely into a superficial dorsal hand vein.
The hand was warmed in a hotbox, which was maintained
at 60°C to achieve adequate arterialisation [14]. In the same
arm, a second cannula was inserted in a forearm antecubital
vein for the infusion of [
2H5]glycerol tracer and the non-
selective beta-adrenergic agonist isoprenaline at a rate of
20 ng (kg FFM)
−1 min
−1. At this infusion rate, plasma iso-
prenaline concentrations are comparable in lean and obese
participants [3]. Finally, the veins on the anterior abdominal
wall were identified by means of a fibre-optic light source.
In order to obtain adipose tissue venous blood, a 10 cm
22-gauge catheter (Central venous catheter kit Seldinger
technique; Becton Dickinson, Alphen aan den Rijn, the
Netherlands) was introduced anterogradely over a guide
wire into one of the superficial veins and threaded towards
the groin, so that its tip lay just superior to the inguinal
ligament [15]. This method provides the drainage from the
adipose tissue of the abdomen, uncontaminated by muscle
drainage and with only a minor contribution from skin [15].
The adipose vein was kept patent by continuous saline
(9 g/l NaCl) infusion at a rate of 80 ml/h. The participants
rested in a supine position for the duration of the study.
Analytical methods
A small portion of blood was used to measure oxygen
saturation (%HbO2) and ensure adequate arterialisation
(ABL510; Radiometer, Copenhagen, Denmark). Blood
was collected in tubes containing EDTA and immediately
centrifuged for 10 min at 1,000g, 4°C. The plasma was
removed for enzymatic colorimetric quantification of NEFA
(NEFA C kit; Wako, Neuss, Germany), glycerol (Boehringer,
Mannheim, Germany) and TAG (Sigma, St Louis, MO,
USA)onacentrifugalspectrophotometer(CobasFara;Roche
Diagnostica, Basel, Switzerland). Plasma glucose concentra-
tion (ABX Diagnostics, Montpellier, France) was measured
on an automated spectrophotometer (Cobas Mira; Roche
Diagnostica). Plasma insulin was measured with a double
antibody radioimmunoassay (Linco Research, St Charles,
MO, USA). Insulin sensitivity was assessed by the ho-
meostasis model assessment index for insulin resistance,
calculated from fasting glucose and insulin [16]. Packed
cell volume was measured using a microcapillary system
(Hirschmann Laborgeräte, Eberstadt, Germany).
Isotope enrichment
To determine isotopic enrichment of glycerol, samples first
were derivatised. Acetone (1 ml) was added to 150 μl plasma
and each tube was vortexed for 2 min and centrifuged for
20 min at 17,500g, 4°C. The supernatant fraction was
transferred to a clean tube and dried under nitrogen at 37°C
and derivatised by adding 80 μl ethyl acetate (cat. no. 45765;
Sigma-Aldrich, Seelze, Germany) and 80 μl heptafluoro-
butyricacidanhydride(cat.no.63164;PierceBiotechnology,
Rockford, IL, USA). The tubes were vortexed for 2 min and
incubated for 1 h at 70°C. Samples were than rotated end
over end for 5 min at 25°C and evaporated under nitrogen
at room temperature. Ethyl acetate (70 μl) was added before
injection into the GC-MS (Finnigan MAT 252, Bremen,
Germany) for measurement of glycerol enrichment. Stable
isotope enrichment was analysed by selectively monitoring
the mass to charge ratio (m/z) of molecular ions 253 and
257 for glycerol [17].
Calculations
The net exchange (flux) of metabolites across abdominal
SAT was calculated by multiplying the arterio–venous con-
centration difference of metabolites by adipose tissue plasma
flow. Plasma flow was calculated as ATBF×(1–packed cell
volume), with packed cell volume expressed as a fraction. A
positive net flux indicates net uptake from plasma, whereas
a negative net flux indicates net tissue release.
The expected adipose vein enrichment, in case of no
glycerol uptake, was calculated as arterialised enrichment
multiplied by arterialised glycerol concentration divided by
the measured adipose vein enrichment.
The Ra of glycerol was calculated according to the
following steady-state equation:
Ra μmol kg 1 min
 1

¼ TTR
 1  F
where TTR is tracer/tracee ratio and F is the isotope
infusion rate (μmol kg
−1 min
−1).
The fractional extraction (fract) of glycerol across
abdominal SAT was calculated by dividing the arterio–
venous concentration difference of [
2H5]glycerol by the
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2H5]glycerol concentration. Abdominal SAT total
glycerol uptake was calculated as follows:
abdominal SATtotalglyceroluptake
¼ fract  glycerolart ðÞ   ATBF
where the units are nmol (100 g tissue)
−1 min
−1; (glycerolart)
is arterialised glycerol concentration (μmol/l); and ATBF is
in ml (100 g tissue)
−1 min
−1. Abdominal SAT total glycerol
release was calculated from the formula:
abdominal SATtotalglycerolrelease
¼ abdominal SATnetglycerolflux
  abdominal SATtotalglyceroluptake
Statistical analysis
Baseline fasting values and changes (Δbeta-adrenergic
stimulation to baseline) were compared between groups
(obese vs lean) using Student’s unpaired t test. Statistical
calculations were performed with SPSS for Macintosh
(version 11.0; SPSS, Chicago, IL, USA). Data are presented
as mean±SEM. A value of p<0.05 was considered statis-
tically significant.
Results
Characteristics
Obese participants had significantly higher BMI, FM, waist
to hip ratio, fasting circulating TAG and insulin concentra-
tions than their lean counterparts (Tables 1 and 2).
Tracer/tracee ratio
Inthepilotexperiment,thetracer/traceeratios(TTR)obtained
during a 6 h [
2H5]glycerol infusion after an overnight fast
were examined (n=3). Arterialised and adipose vein TTR
reached a steady-state after 1 h of infusion (Fig. 1). Mean
values are presented, as all participants (n=3) showed the
same pattern. The measured adipose vein enrichment was
consistently lower than the expected enrichment, implying
uptake of glycerol by adipose tissue. In the actual SAT
lipolysis experiment (3 h [
2H5]glycerol infusion), TTR also
reached a steady-state after 1 h and remained stable during
isoprenaline infusion. Data in lean and obese men were
comparable (data not shown).
Circulating metabolites
Beta-adrenergic stimulation with isoprenaline increased
arterialised TAG concentrations in obese participants, while
in lean participants TAG concentrations decreased during
isoprenaline infusion (Table 2). Thus, the change in
arterialised TAG concentrations from baseline to isoprena-
line was different between obese and lean participants
(ΔTAG obese vs lean, 100±37 vs −45±22 μmol/l, p<0.05;
Table 2).
Furthermore, beta-adrenergic stimulation increased arte-
rialised NEFA and glycerol concentrations in lean and
obese participants. The beta-adrenergic mediated increase
in arterialised NEFA (ΔNEFA 454±68 vs 271±46 μmol/l,
p<0.05) and glycerol concentration (Δglycerol 40±8 vs
15±5 μmol/l, p<0.05) was more pronounced in obese than
inleanparticipants(Table2), suggesting a higher whole-body
lipolytic response in the former. Indeed, beta-adrenergic
stimulation increased whole-body glycerol Ra in lean and
obese participants (Table 2), this increase tending to be
higher intheobesegroup(ΔglycerolRa obese vs lean: 172±
19 vs 109±13 μmol/min, p=0.07; Table 2). Expressed per
unit of FM, fasting glycerol Ra was significantly reduced in
obese compared with lean participants (p<0.05; Table 2).
Interestingly, the beta-adrenergically mediated increase in
glycerol Ra per unit of FM was significantly blunted in
obese participants [Δglycerol Ra per unit FM: 5.4±0.9 vs
7.7±1.5 μmol (kg FM)
−1 min
−1, p<0.05] (Table 2), sug-
Table 2 Circulating (arterialised) metabolite levels during baseline (fasting) and isoprenaline infusion in lean and obese participants
Lean Obese
Baseline (n=13) Isoprenaline (n=10) Baseline (n=10) Isoprenaline (n=7)
TAG (μmol/l) 701±66 648±64 1,464±190
b 1,667±217
a
NEFA (μmol/l) 661±41 942±53 638±42 1,124±82
a
Glycerol (μmol/l) 102±5 118±7 106±4 147±10
a
Glycerol Ra (μmol/min) 199±12 311±28 220±15 391±30
Glycerol Ra/FM [μmol (kg FM)
−1 min
−1] 13.1±0.9 20.9±1.6 7.3±0.6
b 12.9±1.1
a
Glucose (mmol/l) 5.3±0.1 5.4±0.1 5.5±0.2 5.4±0.1
Insulin (pmol/l) 50±4 74±6 94±7
b 167±16
a
Values are mean±SEM
bp<0.05 baseline obese vs lean;
ap<0.05 change (Δ) from baseline obese vs lean using unpaired Student’s t test
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participants.
Finally, beta-adrenergic stimulation increased arterialised
insulinconcentrationsinleanandobeseparticipants(Table2).
This increase in circulating insulin levels was significantly
higher in obese than in lean participants (Δinsulin 62±13
vs 25±4 pmol/l, p<0.05; Table 2).
Abdominal SAT lipolysis
Glycerol uptake by abdominal SAT was observed in lean
and obese participants after an overnight fast (Fig. 2a).
Fractional extraction of [
2H5]glycerol from the circulation
(lean vs obese, 16.6±4.5 vs 13.9±6.7%) and total glycerol
uptake expressed relative to total glycerol release were very
small (lean vs obese, 9.7±3.4 vs 9.3±2.5% of total release)
with no significant difference between lean and obese
participants (p=0.74 and p=0.92, respectively). Adipose
tissue total glycerol uptake increased during beta-adrenergic
stimulation in lean and obese participants, but this increase
was not significantly different between groups [Δ total
glycerol uptake obese vs lean, 4±9 vs 21±5 nmol (100 g
tissue)
−1 min
−1, p=0.15] (Fig. 2a). The increased total glyc-
erol uptake during beta-adrenergic stimulation appeared
to be partly explained by the increase in ATBF (r=0.633,
p<0.05).
Fasting net glycerol and NEFA release across abdominal
SAT were comparable between lean and obese participants
(Table 3). Beta-adrenergic stimulation increased net NEFA
and glycerol release across abdominal SAT to a greater
extent in lean than in obese participants, although changes
were not significantly different between groups (Table 3).
In line with these findings, the beta-adrenergically mediated
increase in total glycerol release across abdominal SAT was
blunted in the obese group [Δ total glycerol release obese
vs lean, 140±71 vs 394±112 nmol (100 g tissue)
−1 min
−1,
p<0.05] (Fig. 2b), suggesting a blunted lipolytic response
per unit of abdominal SAT in obese participants. Finally,
obese men tended to show an increased net TAG flux
across abdominal SAT during beta-adrenergic stimulation
[Δ net TAG flux obese vs lean, 75±32 vs 16±11 nmol
(100 g tissue)
−1 min
−1, p=0.06] (Table 3).
Discussion
The present study was designed to investigate in vivo
whole-body and abdominal SAT lipolysis in obese and lean
men. To our knowledge, this is the first study to show in
vivothatobeseparticipantshaveabluntedbeta-adrenergically
mediated lipolytic response per unit of adipose tissue.
Methodological considerations
A point of discussion with studies on glycerol uptake and
release using tracer methodology is the infusion time of the
labelled glycerol. In previous studies, the infusion time was
relatively short (1–3 h), raising the question of whether
equilibration between labelled glycerol and the adipose
tissue glycerol pool is complete or not [9, 10]. We inves-
tigated glycerol enrichment during a 3 h and 6 h period
of [
2H5]glycerol infusion. Steady-state levels in labelled
[
2H5]glycerol were achieved in arterialised and adipose vein
enrichment after 1 h and remained constant for the sub-
sequent 5 h. Thus, our data support the use of a relatively
short infusion time (1 h) for study of glycerol metabolism.
Fig. 2 Total glycerol uptake (a) and release (b) across abdominal SAT
after an overnight fast (black bars) and during beta-adrenergic stim-
ulation (white bars) in obese vs lean participants during 3 h [
2H5]
glycerol infusion. Values are mean±SEM. *p<0.05 for change (Δ)
from baseline obese vs lean
Fig. 1 Plasma glycerol TTR during 6 h primed constant infusion of
[
2H5]glycerol (n=3) in arterialised blood (squares) and blood draining
from abdominal SAT (adipose vein; black circles). White circles,
expected adipose vein enrichment. The measured adipose vein
enrichment was consistently lower than the expected enrichment
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The present data show a slight glycerol uptake by abdominal
SATof lean and obese participants. Glycerol uptake was not
significantly different between lean and obese participants.
Uptake and dilution of [
2H5]glycerol across abdominal SAT
has been shown previously during 1 h [9] of tracer infusion.
In this study, the dilution of the labelled glycerol was con-
sistently greater than expected from the measured net
release of glycerol, indicating significant uptake of glycerol
by adipose tissue. In line with this study, we observed a
two- to fivefold higher glycerol enrichment in arterialised
than in venous blood draining adipose tissue. The observed
enrichment in venous blood was universally lower than that
predicted from the net addition of glycerol to venous blood.
This indicates that an exchange must occur between
enriched glycerol in the blood and the unenriched non-
esterified glycerol pool in adipose tissue. In contrast, some
studies were unable to detect significant uptake of glycerol
by adipose tissue after 1 h of tracer infusion [10]. The reason
for this apparent discrepancy remains to be elucidated. It
should be mentioned that glycerol uptake is low in human
adipose tissue as is the activity of the enzyme glycerol
kinase [18]. This enzyme is responsible for the phosphor-
ylation of glycerol into glycerol 3-phosphate, making it
available for re-esterification.
Abdominal SAT lipolytic response to beta-adrenergic
stimulation
A blunted isoprenaline-induced increase in total glycerol
release per unit abdominal SATwas observed in obese men,
indicating that in vivo beta-adrenergic mediated lipolytic
response in abdominal SAT of obese participants is blunted.
Our data are consistent with evidence of catecholamine
resistance in vitro and in situ in obese individuals [2–4], in
children with obesity [5, 6] and also in relatives of obese
individuals [7]. Defects in catecholamine signal transduc-
tion have been observed at the β2-adrenoceptor level and
further downstream or directly involving hormone-sensitive
lipase [8, 19–22]. However, from our experiments it is not
possible to determine at which level the observed defect is
located. Interestingly, catecholamine resistance has been
observed in adipose tissue of first-degree relatives of obese
participants [7] and persists after weight reduction [4], sug-
gesting that catecholamine resistance may be a primary
defect inobesity.Furthermore,plasma insulin concentrations
may play an important role in regulating lipolysis [23].
Therefore, we cannot fully rule out the possibility that the
blunted lipolytic response per unit adipose tissue mass that
we observed is a secondary phenomenon, due to the higher
degree of hyperinsulinaemia during beta-adrenergic stimu-
lation in obese compared with lean participants. However,
this explanation seems unlikely, since a blunted in situ
lipolytic response in abdominal SAT of obese women was
still observed when the confounding influence of hyper-
insulinaemia had been excluded using a pancreatic hormonal
clamp [2].
In contrast to the present study, two in situ microdialysis
studies performed in men found that the increase in
interstitial glycerol during isoprenaline administration did
not differ between lean and obese individuals [24, 25]. A
possible explanation for this is that in microdialysis studies
interstitial glycerol is used as a measure of lipolysis. Since
glycerol is taken up by adipose tissue, interstitial glycerol
concentration may not reflect the overall rate of lipolysis.
Rather, it may be the net result of TAG and glycerol metab-
olism, thus reflecting net glycerol turnover [26].
Whole-body beta-adrenergically mediated lipolytic
response
Whole-body lipolytic response during isoprenaline infusion
tended to be higher in obese participants. This was reflected
by a higher increase in circulating NEFA and glycerol
concentrations during beta-adrenergic stimulation in obese
Table 3 Blood flow and net
SAT fluxes during baseline
(fasting) and isoprenaline
infusion in lean and obese
participants
Values are mean±SEM
A positive net flux indicates net
uptake from plasma, whereas a
negative net flux indicates net
tissue release
ap<0.05 baseline obese vs lean
using unpaired Student’s t test
Lean Obese
Baseline
(n=13)
Isoprenaline
(n=10)
Baseline
(n=10)
Isoprenaline
(n=7)
ATBF [ml (100 g tissue)
−1 min
−1] 2.2±0.2 6.3±1.2 1.4±0.2
a 3.6±0.6
Net SAT fluxes
[nmol (100 g tissue)
−1 min
−1]
TAG 25±8 43±17 34±29 113±62
NEFA −780±160 −2,101±371 −486±101 −1,824±667
Glycerol −229±49 −640±148 −211±51 −486±128
Glucose 53±49 −69±151 −143±96 −677±632
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adrenergically mediated lipolysis (glycerol Ra) was signif-
icantly lower in obese than in lean men. This suggests
that the increased whole-body beta-adrenergically mediated
lipolytic response in obese individuals is directly linked to
the increased adipose tissue mass, as has been shown before
in upper body obese women [2]. Increased release of NEFA
into the circulation increases NEFA delivery to the liver,
resulting in increased hepatic VLDL-TAG output and hence
increased circulating TAG levels during beta-adrenergic
stimulation, as was observed in our obese participants. The
control of whole-body lipid metabolism is, to a large extent,
dependent on the efficient regulation of lipid metabolism in
adipose tissue and the liver. Moreover, hepatic VLDL-TAG
is a precursor of TAG stored in adipose tissue [27, 28].
Consequently, a greater VLDL-TAG delivery to adipose
tissue and greater lipoprotein lipase-mediated hydrolysis
might explain the tendency towards increased positive TAG
flux across abdominal SATof obese participants during beta-
adrenergic stimulation. Our observation is in agreement with
a study by Samra et al. [29] showing an increased rate of
action of lipoprotein lipase during epinephrine infusion.
These in vivo findings are in contrast with in vitro studies
showing that lipoprotein lipase expression and activity are
suppressed by epinephrine [30, 31]. Future studies are
needed to elucidate whether an increased TAG flux across
SAT might contribute to the increased TAG storage in adi-
pose tissue of obese participants.
Conclusion
The present study demonstrates in vivo that obese men have
a blunted beta-adrenergically mediated lipolytic response in
abdominal SAT. Therefore, a blunted lipolysis during beta-
adrenergic stimulation may be an important factor in the
development or maintenance of increased TAG stores and
obesity.
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